NBC Securities’s Trevi Therapeutics TRVI Stock Holding History

NBC Securities’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.3K	Sell	2,000 -15,000	-88%	-$218K	﹤0.01%	1404
2026 Q1	$203K	Hold	17,000	–	–	0.02%	829
2025 Q4	$213K	Buy	17,000 +15,000	+750%	+$173K	0.02%	817
2025 Q3	$18.3K	Hold	2,000	–	–	﹤0.01%	1783
2025 Q2	$10K	Hold	2,000	–	–	﹤0.01%	1954
2025 Q1	$12K	Buy	2,000 +1,998	+99,900%	+$9.53K	﹤0.01%	1685
2024 Q4	$8	Sell	2 -1,998	-100%	-$6.4K	﹤0.01%	1216
2024 Q3	$6K	Hold	2,000	–	–	﹤0.01%	1858
2024 Q2	$5K	Hold	2,000	–	–	﹤0.01%	1864
2024 Q1	$6K	Hold	2,000	–	–	﹤0.01%	1836
2023 Q4	$2K	Hold	2,000	–	–	﹤0.01%	2037
2023 Q3	$4K	Buy	+2,000	New	+$4.52K	﹤0.01%	1923

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

NBC Securities's TRVI Position: Q2 2026 in Review

NBC Securities reduced its Trevi Therapeutics (TRVI) stake by 88% in Q2 2026, selling an estimated $218K and leaving 2,000 shares worth $37.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1404.

NBC Securities first reported a position in TRVI in Q3 2023 and has held it in 12 quarters since. The position peaked at $213K in Q4 2025. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

NBC Securities held 2,000 shares of Trevi Therapeutics worth $37.3K as of Q2 2026.
NBC Securities sold 15,000 Trevi Therapeutics shares in Q2 2026, an estimated $218K.
Trevi Therapeutics made up ﹤0.01% of NBC Securities's portfolio in Q2 2026, its #1404 holding.
NBC Securities first reported a position in Trevi Therapeutics in Q3 2023 and has held it in 12 quarters since.
NBC Securities's Trevi Therapeutics position peaked at $213K in Q4 2025.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.